96 Tests PN: A112239

Components:

45x Ab-conjugated beads (S5P2 - human MIP-1α Ab-bead). PN: A112239A. One vial containing 100 µL of anti-human MIP-1α conjugated to AimPlex Bead S5P2.

25x Biotin-detection Ab (human MIP-1α Biotin-dAb). PN: A112239B. One vial containing 100 µL of biotinylated anti-human MIP-1α.

Lyophilized Standard Mix-Human Group 3 Panel A, 8-Plex. PN: HG30008. One vial containing lyophilized recombinant human Fractalkine, LIF, TNFβ, VEGF-D, I-TAC, MIP-1α, MIP-1β, and TIM-1. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human MIP-1α.  Can be multiplexed with other analytes in Human Group 3.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 2 pg/mL

  • Quantitation range:

  • LLOQ: < 2pg/mL

  • ULOQ: > 2,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 3: Negligible

  • Sample volume: 15 µL/test

Description:

Macrophage Inflammatory Protein-1α (Accession P10147) is a CC chemokine that binds to receptors CCR1, CCR4, and CCR5. MIP-1α and MIP-1β are chemoattractants and often function together in recruiting human T lymphocytes. MIP-1α is also a crucial mediator in the inflammatory process and elevated levels are associated with sarcoidosis and Idiopathic pulmonary fibrosis. MIP-1α is also involved in the formation of osteolytic bone lesions that occur in individuals with multiple myeloma, though many other cytokines like IL-6 are believed to play a role in the development of MM. Though as a potential indicator, it may demonstrate to be a key target cytokine for therapies.

References:

  1. Lentzsch S, Gries M, Janz M, Bargou R, Dörken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood. 2003; 101(9): 3568-3573. Doi:10.1182/blood-2002-08-2383.

  2. Standiford TJ, Rolfe MW, Kunkel SL, Lynch III JP, Burdick MD, Gilbert AR, Orringer MB, Whyte RI, Strieter RM. Macrophage inflammatory protein-1 alpha expression in interstitial lung disease. J Immunol. 1993; 151(1): 2852-2863. PubMed 8360496.

  3. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science. 1993; 260(5106): 355-358. Doi: 10.1126/science.7682337.